Back to Directory

Charlotte Perlowski

Email

cperlowski@fhi360.org

Phone

919-321-3581

Institution

FHI 360

Title

Research Associate

Address

FHI 360
359 Blackwell St.
Suite 200
Durham, NC 27701
United States of America

Request an Update

Affiliated Studies

IMPAACT 2035/HVTN 604: Phase I/II Study of the Safety and Immunogenicity of VPM1002 Vaccination and BCG Revaccination against Tuberculosis in Pre-Adolescents Living with and without HIV in South Africa (LEAP)

DAIDS Number

38846

Research Area

Tuberculosis

Study Status

In Development

P1112: Monoclonal Antibody PK Study

DAIDS Number

11903

Research Area

Prevention

Study Status

Closed to Follow Up

IMPAACT 2011: Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID delta M2-2 1030s, Lot RSV#010A, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age

DAIDS Number

30072

Research Area

Complications & Comorbidities

Study Status

Concluded

IMPAACT 2012: Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID cp delta M2-2, Lot RSV#009B, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age

DAIDS Number

30073

Research Area

Complications & Comorbidities

Study Status

Concluded

IMPAACT 2013: Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, D46/NS2/N/delta M2-2-HindIII, Lot RSV#011B, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age

DAIDS Number

30074

Research Area

Complications & Comorbidities

Study Status

Participants Off Study and Primary Analysis Completed

Show All